Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses ongoing research efforts to develop natural anti-androgenetic alopecia treatments using bioactive compounds from medicinal plants but reports no new clinical results.

This study found that individuals with androgenetic alopecia had significantly lower serum vaspin levels than healthy controls, suggesting vaspin deficiency might help detect early-stage androgenic alopecia.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

This study found that using a vibration anesthetic device during scalp mesotherapy significantly reduced pain in patients with androgenetic alopecia and alopecia areata compared to the non-vibration side.

This study found that Avicennia marina extract and its active compound avicequinone C inhibit enzymes and receptors related to androgenic alopecia, potentially supporting hair growth in cultured dermal papilla cells.

The woman's symptoms and tests suggest her adrenal glands are producing too many male hormones.

In this study, AMP-303 injections demonstrated a trend toward increasing non-vellus hair count in men with mild to moderate androgenetic alopecia, notably showing a 14.5% peak increase at 60 days compared to saline, with effects lasting up to five months.

In this case series, three patients with advanced non-small cell lung cancer experienced severe skin eruptions and scarring alopecia after treatment with amivantamab, highlighting the critical need for prompt recognition and management of these adverse effects to minimize treatment interruptions.

This study reported significant improvements in hair density, diameter, and patient satisfaction after using non-enzymatic stromal vascular fraction treatment for androgenic alopecia over six months.

This study found that adipose derived stem cells in areas of alopecia in patients with androgenetic alopecia showed different levels of various signaling proteins compared to other scalp and periumbilical regions.

In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.

This case report described a 29-year-old man with male pattern baldness treated with the lesser-known sarcode Adrenalin, but the abstract does not provide further details on the treatment outcome or efficacy.

AMP-303 injections can increase hair growth in androgenetic alopecia with minimal side effects.

In this study, researchers developed an in vitro airway-organoid model using human lung-derived cell lines on RADA16-I hydrogels to serve as a potential tool for studying adenovirus isolation, pathogenesis, and antiviral drug screening.

This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.

In this study, researchers found that microinfusion of dutasteride using the MMP® technique did not show a statistical difference compared to placebo in clinical assessments for male androgenetic alopecia, though patients reported improvements in the vertex area.

This study found that male patients with androgenetic alopecia were associated with an increased risk of varicose veins, but not other major vascular diseases.

In this case report, a 35-year-old man developed avascular necrosis after receiving intradermal corticosteroid injections for alopecia areata, marking the first documented instance of this side effect from such treatment.

Created microspheres show potential for safe and effective use in prostate artery embolization.

This study suggests that valine and certain VLDL subfractions are positively associated with androgenetic alopecia risk, while reverse analysis showed AGA does not affect these metabolites.

This review discusses the roles of the Agouti and Agouti-related proteins in pigmentation and energy regulation and reports no new experimental findings.

This study found that the protein C4BPA may link insulin resistance and acne vulgaris by influencing lipid metabolism and inflammatory pathways, suggesting it as a potential mediator in the pathogenesis of both conditions.

This case report suggests that scalp arteriovenous malformations can cause local hair loss, which may recover following ethanol embolization treatment.

This study found that vascular endothelial growth factor may protect hair follicle stem cells from androgen-induced apoptosis in androgenic alopecia patients via the PI3K/Akt pathway.

This review discusses the potential of extracellular vesicles as a minimally invasive treatment for androgenetic alopecia, but emphasizes that most research is still in preclinical stages and more clinical trials are needed.

This study found that a single injection of autologous cell micrografts significantly improved hair condition in women with androgenetic alopecia six months post-treatment.

This study found that patients with androgenetic alopecia frequently had higher PSA levels and more significant urinary symptoms, likely due to older age, though prostate weight did not differ.

This paper introduces the Vertex Overload Framework for androgenetic alopecia, suggesting that chronic mechanical and thermal stress on the vertex contributes to hair follicle miniaturization, with androgens acting as co-mediators of stress adaptation rather than isolated causes.

In this study, the authors highlight the potential of intradermal microinjections of dutasteride as an adjunctive therapy for androgenetic alopecia, though they note that information on its effectiveness remains limited.